OBJECTIVE: To estimate whether the association between nevirapine (NVP) and hepatotoxicity differs according to pregnancy status in HIV-infected women. METHODS: The present analysis included HIV-infected pregnant women on antiretroviral therapy (ART) from two multicenter, prospective cohorts - the Women and Infants Transmission Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1025 - and HIV-infected nonpregnant women from one multicenter, prospective cohort - the Women's Interagency HIV Study. Using multivariate Cox proportional hazards regression, the interaction between NVP and pregnancy status in terms of hepatotoxicity was investigated. NVP use was dichotomized as use or no use and was further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation (LEE; grade 1-4) and severe LEE (grade 3-4). RESULTS: Data on 2050 HIV-infected women taking ART were included: 1229 (60.0%) pregnant and 821 (40.0%) nonpregnant. Among the pregnant women, 174 (14.2%) developed any LEE and 15 (1.2%) developed severe LEE as compared with 75 (9.1%) and 5 (0.6%), respectively, of the nonpregnant women. In multivariate adjusted models, NVP was not significantly associated with risk of LEE, regardless of pregnancy status; however, pregnancy was associated with an increased risk of any LEE (relative risk 4.7, confidence interval = 3.4-6.5) and severe LEE (relative risk 3.8, confidence interval = 1.3-11.1). The association of pregnancy and LEE was seen, regardless of prior ART and NVP exposure history. CONCLUSION: No significant association between NVP and LEE was observed, regardless of pregnancy status, but pregnancy was significantly associated with increased hepatotoxocity in HIV-infected women.
OBJECTIVE: To estimate whether the association between nevirapine (NVP) and hepatotoxicity differs according to pregnancy status in HIV-infectedwomen. METHODS: The present analysis included HIV-infected pregnant women on antiretroviral therapy (ART) from two multicenter, prospective cohorts - the Women and Infants Transmission Study and the International Maternal Pediatric Adolescent AIDS Clinical Trials protocol P1025 - and HIV-infected nonpregnant women from one multicenter, prospective cohort - the Women's Interagency HIV Study. Using multivariate Cox proportional hazards regression, the interaction between NVP and pregnancy status in terms of hepatotoxicity was investigated. NVP use was dichotomized as use or no use and was further categorized according to ART exposure history. We investigated two outcomes: any liver enzyme elevation (LEE; grade 1-4) and severe LEE (grade 3-4). RESULTS: Data on 2050 HIV-infectedwomen taking ART were included: 1229 (60.0%) pregnant and 821 (40.0%) nonpregnant. Among the pregnant women, 174 (14.2%) developed any LEE and 15 (1.2%) developed severe LEE as compared with 75 (9.1%) and 5 (0.6%), respectively, of the nonpregnant women. In multivariate adjusted models, NVP was not significantly associated with risk of LEE, regardless of pregnancy status; however, pregnancy was associated with an increased risk of any LEE (relative risk 4.7, confidence interval = 3.4-6.5) and severe LEE (relative risk 3.8, confidence interval = 1.3-11.1). The association of pregnancy and LEE was seen, regardless of prior ART and NVP exposure history. CONCLUSION: No significant association between NVP and LEE was observed, regardless of pregnancy status, but pregnancy was significantly associated with increased hepatotoxocity in HIV-infectedwomen.
Authors: M Homma; K Beckerman; S Hayashi; A L Jayewardene; K Oka; J G Gambertoglio; F T Aweeka Journal: J Pharm Biomed Anal Date: 2000-09 Impact factor: 3.935
Authors: N A Hessol; M Schneider; R M Greenblatt; M Bacon; Y Barranday; S Holman; E Robison; C Williams; M Cohen; K Weber Journal: Am J Epidemiol Date: 2001-09-15 Impact factor: 4.897
Authors: Jerry O Stern; Patrick A Robinson; James Love; Stephan Lanes; Michael S Imperiale; Douglas L Mayers Journal: J Acquir Immune Defic Syndr Date: 2003-09 Impact factor: 3.731
Authors: Alejandro Dorenbaum; Coleen K Cunningham; Richard D Gelber; Mary Culnane; Lynne Mofenson; Paula Britto; Claire Rekacewicz; Marie-Louise Newell; Jean Francois Delfraissy; Bethann Cunningham-Schrader; Mark Mirochnick; John L Sullivan Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: Ferdinand W N M Wit; Gerrit Jan Weverling; Jan Weel; Suzanne Jurriaans; Joep M A Lange Journal: J Infect Dis Date: 2002-06-14 Impact factor: 5.226
Authors: T J Nagu; M Kanyangarara; C Hawkins; E Hertmark; G Chalamila; D Spiegelman; F Mugusi; W Fawzi Journal: HIV Med Date: 2012-03-14 Impact factor: 3.180
Authors: Elizabeth G Livingston; Yanling Huo; Kunjal Patel; Susan B Brogly; Ruth Tuomala; Gwendolyn B Scott; Arlene Bardeguez; Alice Stek; Jennifer S Read Journal: Obstet Gynecol Date: 2010-08 Impact factor: 7.661
Authors: Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema Journal: Drug Saf Date: 2013-10 Impact factor: 5.606
Authors: Susie Huntington; Claire Thorne; Marie-Louise Newell; Jane Anderson; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline Sabin Journal: AIDS Date: 2015-04-24 Impact factor: 4.177
Authors: Susie E Huntington; Loveleen K Bansi; Claire Thorne; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin Journal: BMC Med Res Methodol Date: 2012-07-28 Impact factor: 4.615